At the 2026 semi-annual performance briefing held on September 8, Zhaoyan New Pharmaceutical said that from the demand side, domestic innovative drug financing and BD licensing transactions continued to pick up in 2026, leading to a sharp increase in overall industry demand for non-human primate experimental models; from the supply side, the breeding rate of non-human primate experimental animals is relatively stable, and the industry's supply elasticity is low, and production cannot expand rapidly. Therefore, domestic supply and demand for non-human primate experimental animals is tight, and prices have increased accordingly.

At the 2026 semi-annual performance briefing held on September 8, Zhaoyan New Pharmaceutical said that from the demand side, domestic innovative drug financing and BD licensing transactions continued to pick up in 2026, leading to a sharp increase in overall industry demand for non-human primate experimental models; from the supply side, the breeding rate of non-human primate experimental animals is relatively stable, and the industry's supply elasticity is low, and production cannot expand rapidly. Therefore, domestic supply and demand for non-human primate experimental animals is tight, and prices have increased accordingly.